Squarepoint Ops LLC Grows Position in Kymera Therapeutics, Inc. (NASDAQ:KYMR)

Squarepoint Ops LLC boosted its stake in shares of Kymera Therapeutics, Inc. (NASDAQ:KYMR) by 27.3% in the 2nd quarter, according to its most recent disclosure with the SEC. The institutional investor owned 108,563 shares of the company’s stock after acquiring an additional 23,312 shares during the period. Squarepoint Ops LLC’s holdings in Kymera Therapeutics were worth $3,241,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds also recently bought and sold shares of the stock. Comerica Bank boosted its holdings in shares of Kymera Therapeutics by 13.7% during the 1st quarter. Comerica Bank now owns 3,324 shares of the company’s stock valued at $134,000 after purchasing an additional 400 shares during the last quarter. Public Employees Retirement Association of Colorado bought a new position in Kymera Therapeutics during the second quarter valued at approximately $139,000. Quest Partners LLC boosted its stake in Kymera Therapeutics by 1,402.0% during the second quarter. Quest Partners LLC now owns 5,212 shares of the company’s stock valued at $156,000 after buying an additional 4,865 shares during the last quarter. Ameritas Investment Partners Inc. increased its stake in Kymera Therapeutics by 7.8% in the 1st quarter. Ameritas Investment Partners Inc. now owns 4,070 shares of the company’s stock worth $164,000 after acquiring an additional 295 shares during the last quarter. Finally, XTX Topco Ltd bought a new stake in Kymera Therapeutics in the 2nd quarter worth approximately $201,000.

Kymera Therapeutics Stock Down 1.6 %

Shares of Kymera Therapeutics stock opened at $46.57 on Wednesday. The stock’s fifty day moving average is $45.95 and its two-hundred day moving average is $39.42. Kymera Therapeutics, Inc. has a 52 week low of $9.60 and a 52 week high of $53.27. The company has a market capitalization of $2.86 billion, a PE ratio of -18.55 and a beta of 2.22.

Kymera Therapeutics (NASDAQ:KYMR) last posted its quarterly earnings results on Wednesday, August 7th. The company reported ($0.58) EPS for the quarter, topping the consensus estimate of ($0.68) by $0.10. Kymera Therapeutics had a negative net margin of 178.27% and a negative return on equity of 28.88%. The company had revenue of $25.60 million for the quarter, compared to the consensus estimate of $12.55 million. During the same quarter last year, the firm posted ($0.67) EPS. The firm’s revenue was up 55.2% compared to the same quarter last year. As a group, research analysts anticipate that Kymera Therapeutics, Inc. will post -2.87 earnings per share for the current year.

Analyst Ratings Changes

Several equities research analysts recently weighed in on the stock. HC Wainwright restated a “buy” rating and issued a $46.00 price target on shares of Kymera Therapeutics in a research report on Monday, June 17th. Wells Fargo & Company boosted their target price on shares of Kymera Therapeutics from $30.00 to $38.00 and gave the stock an “equal weight” rating in a report on Monday, August 12th. B. Riley increased their price target on shares of Kymera Therapeutics from $31.00 to $36.00 and gave the company a “neutral” rating in a report on Tuesday, July 9th. Leerink Partnrs raised Kymera Therapeutics to a “strong-buy” rating in a research note on Monday, September 9th. Finally, Oppenheimer raised their price objective on Kymera Therapeutics from $52.00 to $56.00 and gave the company an “outperform” rating in a research note on Friday, September 27th. Four analysts have rated the stock with a hold rating, eight have assigned a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average price target of $49.00.

Insider Transactions at Kymera Therapeutics

In related news, Director Bruce Booth sold 453,960 shares of the business’s stock in a transaction that occurred on Tuesday, July 9th. The stock was sold at an average price of $38.21, for a total value of $17,345,811.60. Following the completion of the sale, the director now owns 723,246 shares in the company, valued at $27,635,229.66. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. In related news, Director Bruce Booth sold 453,960 shares of the company’s stock in a transaction dated Tuesday, July 9th. The shares were sold at an average price of $38.21, for a total value of $17,345,811.60. Following the completion of the sale, the director now directly owns 723,246 shares of the company’s stock, valued at $27,635,229.66. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, Director Pamela Esposito sold 13,500 shares of the stock in a transaction dated Tuesday, September 17th. The stock was sold at an average price of $48.28, for a total transaction of $651,780.00. The disclosure for this sale can be found here. Over the last three months, insiders have sold 495,605 shares of company stock valued at $19,303,364. 15.82% of the stock is currently owned by company insiders.

About Kymera Therapeutics

Kymera Therapeutics, Inc, a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors.